Recent strategies to achieve high production yield of recombinant protein: A review

Tepap, Cromwel Zemnou; Anissi, Jaouad; Bounou, Salim

doi:10.3233/jcb-220084

Cited by 3 publications

(2 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, the above-described bsAbs formats and numerous expression systems, such as B. subtilis, Streptomyces, yeast, transgenic plants, transgenic animals, and insect cells, are still ineffective in producing large quantities of recombinant proteins and are rarely used in antibody production [79].…”

Section: Discussionmentioning

confidence: 99%

State-of-the-Art Approaches to Heterologous Expression of Bispecific Antibodies Targeting Solid Tumors

Misorin,

Chernyshova,

Karbyshev

2023

Biochemistry Moscow

View full text Add to dashboard Cite

Bispecific antibodies (bsAbs) are some of the most promising biotherapeutics due to the versatility provided by their structure and functional features. bsAbs simultaneously bind two antigens or two epitopes on the same antigen. Moreover, they are capable of directing immune effector cells to cancer cells and delivering various compounds (radionuclides, toxins, and immunologic agents) to the target cells, thus offering a broad spectrum of clinical applications. Current review is focused on the technologies used in bsAb engineering, current progress and prospects of these antibodies, and selection of various heterologous expression systems for bsAb production. We also discuss the platforms development of bsAbs for the therapy of solid tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

State-of-the-Art Approaches to Heterologous Expression of Bispecific Antibodies Targeting Solid Tumors

Misorin,

Chernyshova,

Karbyshev

2023

Biochemistry Moscow

View full text Add to dashboard Cite

show abstract

“…It has been reported in culture media, whether intracellular or secretory. 40 For example, most cell lines are derived from the ovaries of the fall armyworm, Spodoptera frugiperda (Sf9, Sf21) and Trichoplusia ni , (Tn5 or High Five TM). These cells are used to produce recombinant proteins.…”

Section: Introductionmentioning

confidence: 99%

Cloning, expression and molecular analysis of recombinant Netrin-A protein of Lucilia sericata Meigen (Diptera: Calliphoridae) larvae

Moemenbellah-Fard,

Bagheri,

Bonyani

et al. 2024

SAGE Open Medicine

View full text Add to dashboard Cite

Objectives: Lucilia sericata (Diptera: Calliphoridae) is used in larval therapy for wound healing. Netrin-A is an enzyme secreted from the salivary glands of these larvae, and has a central role in neural regeneration and angiogenesis. This study aimed to produce the recombinant Netrin-A protein from Lucilia sericata larvae by the baculovirus expression vector system in the Sf9 insect cell line. Methods: The coding sequence of Netrin-A was cloned, amplified in the pTG19 vector, and then cloned in the pFastBac HTA vector. It was then transformed into DH10Bac, and the recombinant Bacmid was subsequently transfected into Sf9 cells. The recombinant Netrin-A was purified by Ni-NTA agarose. The evaluation was done using SDS-PAGE and western blot, respectively. Finally, its concentration was calculated with the Bradford assay. Results: The molecular weight of this protein was 52 kDa with 404 amino acids. The signal peptide was located between amino acids 24 and 25. The concentration of Netrin-A was calculated to be 48.8 μg/ml. It reaffirmed the characterized gene codes of Lucilia sericata Netrin-A in a previous study. Conclusions: The generation of recombinant Netrin-A could be used in larval therapy, and as a biomarker in certain diseases. The netrin-A of Lucilia sericata was unprecedentedly cloned and expressed in a eukaryotic cell line. Given that this larva is FDA-approved, and non-pathogenic, it conduces to research on the development of maggot therapy in future.

show abstract

State-of-the-art approaches for heterologous expression of bispecific antibodies targeting solid tumors

Misorin,

Chernyshova,

Karbyshev

2023

Biohimiâ

View full text Add to dashboard Cite

Bispecific antibodies (bsAbs) belong to the group of promising biotherapeutics, as their structural and functional features provide versatility. To put it simply, bsAbs bind two antigens or two epitopes on one antigen simultaneously, moreover, they are capable of directing effector immune cells to cancer cells and delivering payloads (radionuclides, toxic agents, and immunological payloads) to target cells, thus offering a broad spectrum of clinical applications. Current review is focused on bsAbs platform engineering technologies, current progress and prospects in utilization and selection of various heterologous expression systems for protein production. Furthermore we share our view on the future of the bsAbs development for solid tumor therapy.

show abstract

Recent strategies to achieve high production yield of recombinant protein: A review

Cited by 3 publications

References 107 publications

State-of-the-Art Approaches to Heterologous Expression of Bispecific Antibodies Targeting Solid Tumors

State-of-the-Art Approaches to Heterologous Expression of Bispecific Antibodies Targeting Solid Tumors

Cloning, expression and molecular analysis of recombinant Netrin-A protein of Lucilia sericata Meigen (Diptera: Calliphoridae) larvae

State-of-the-art approaches for heterologous expression of bispecific antibodies targeting solid tumors

Contact Info

Product

Resources

About